secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2026-08-12T10:30:30+00:00
Accession:  0001104659-26-094391
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q4 revenue $321M, adjusted EPS $0.52; dividend $0.08; Merck deal on track
--------------------------------------------------------------------------------

- Q4 revenue $321.2M (+1% reported, +3% organic); FY26 flat at $1.2B
- Q4 GAAP EPS $0.35 vs $(0.11) prior year; adjusted EPS $0.52 vs $0.53
- FY26 GAAP EPS $1.16 vs $0.46; adjusted EPS $1.93 vs $1.92
- Quarterly dividend $0.08/share, payable Sept 4, 2026, record Aug 24
- Merck KGaA acquisition at $73/share cash, ~$11.3B EV, on track

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/0001104659-26-094391-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000110465926094391/tech-20260812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094391

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer